Merck & Co., Inc. (MRK) compounding analysis
Full-size annual and quarterly year-over-year growth charts for revenue, EPS, operating cash flow, EBITDA, and free cash flow against the 15%, 20%, and 30% bars over 3-, 5-, and 10-year windows, with each metric's valuation multiple vs its own history.
Revenue · 5YDoes not currently clear the 15%+, 20%+, or 30%+ revenue bars over 5Y.
- Score
- 24/100
- 5Y CAGR
- 9.4%
- Median YoY
- 6.2%
- YoY volatility
- σ 12.7pp· uneven
- Quarters ≥ 20%
- 4 of 20
- Negative quarters
- 3
- Valuation vs own 5Y history
- P/S 4.9x · 5Y median 4.5x · 85th percentile
How this score is computed
- Quarters at or above 20%: 4 of 20 → 8 of 40 pts
- Steadiness (typical swing 12.7pp) → 15.9 of 25 pts
- Pace (median 6.2% YoY) → 0 of 20 pts
- Latest quarter (4.3% YoY) → 0 of 15 pts
- Score: 24 of 100
Annual revenue · last 11 fiscal years
Quarterly YoY revenue growth vs the 20% line · 5Y
P/S multiple vs its 5Y median · context only
Across metrics · 5Y
| Metric | 5Y CAGR | Median YoY | YoY σ | Qtrs ≥ 20% | Neg. qtrs |
|---|---|---|---|---|---|
| RevenueRevenue | 9.4% | 6.2% | 12.7pp | 4 of 20 | 3 |
| EPSEPS | 21.2% | — | — | — | — |
| Op cash flowOperating cash flow | 9.9% | 18.6% | 294.2pp | 10 of 20 | 9 |
| EBITDAEBITDA | 26.6% | — | — | — | — |
| FCFFree cash flow | 16.2% | 24.2% | 187.2pp | 10 of 18 | 8 |
Reported figures over 5Y: annual-series CAGR, median and standard deviation (σ, percentage points) of quarterly year-over-year growth, quarters at or above 20%, and quarters with negative YoY. “—” means the window needs more comparable data.
Scores, qualification bars, and the 0–100 consistency methodology are documented on the compounders list page →
See also: MRK on the compounders surface · All compounders, ranked
About Merck & Co., Inc.
Merck & Co., Inc. is a global healthcare leader with operations spanning two core divisions: Pharmaceuticals and Animal Health. The Pharmaceutical segment is dedicated to human health, offering a broad spectrum of medicinal products. These cover crucial therapeutic areas such as oncology, acute hospital care, immunology, neuroscience, virology, cardiovascular conditions, and diabetes. This division also develops vital preventive vaccines for pediatric, adolescent, and adult populations. Meanwhile, the Animal Health segment focuses on the research, development, manufacturing, and marketing of veterinary medications, vaccines, and comprehensive health management solutions for animals. This division further provides innovative digital products designed for animal identification, traceability, and continuous monitoring. Merck's extensive clientele encompasses drug wholesalers, pharmacies, hospitals, and government agencies. It also serves managed healthcare organizations, including health maintenance organizations (HMOs) and pharmacy benefit managers, as well as various other institutional clients. Additionally, the company supplies products to individual physicians and their distributors, veterinarians, and livestock producers. The organization actively engages in strategic collaborations with companies such as AstraZeneca PLC, Bayer AG, Eisai Co., Ltd., Ridgeback Biotherapeutics, and Gilead Sciences, Inc. These partnerships are specifically aimed at the joint development and commercialization of prolonged-acting therapies for HIV. Established in 1891, Merck & Co., Inc. maintains its corporate headquarters in Kenilworth, New Jersey.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- CEO
- Robert Davis